Although a relatively new company, Absolute Antibody has a vast array of experience in humanization with many of the leadership team having developed the approved therapeutic antibody CAMPATH-1H (alemtuzumab). This was the first therapeutically relevant antibody to be humanized (1) and the first to reach the clinic in 1988 (2).
Based on this legacy in humanization and more recent advances, Absolute Antibody offers a royalty free humanization service for antibodies from any species.
|Electronic sequence or hybridoma||0.5 mg IgGs||Hybridoma sequencing (if required), production of parental IgG and chimeric human IgG controls, confirmation of expected activity for controls, humanization, production of a panel of humanized IgGs, comparison of activity with controls.||Dependant on range of services required.||Sequences of parental IgG and all humanized variants, 0.5mg of parental IgG, chimeric human IgG and all humanized variants.|
1 – Riechmann, Clark, Waldmann, Winter 1988. Reshaping human antibodies for therapy. Nature.
2 – Hale, Dyer, Clark, Phillips, Marcus, Riechmann, Winter, Waldmann 1988. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet.